Overview

The Prevstain Trial

Status:
Not yet recruiting

Trial end date:
2021-12-28

Target enrollment:

Participant gender:

Summary

To evaluate whether oral supplementation with Pycnogenol (Flebon®) can interfere with skin hyperpigmentation after polidocanol foam sclerotherapy in patients with mild to moderate chronic venous insufficiency (CEAP C2 and C3) compared with the use of Placebo.

Phase:

Phase 2

Details

Lead Sponsor:

University of Sao Paulo General Hospital

Treatments:

Pycnogenols